Clinical Sequencing

Researchers will analyze tumor samples via NGS to try and identify genomic alterations that explain patients' drug response. 

Flagship Bio is using ACD's RNAscope and customizing and optimizing the technology for use in CLIA clinical trials with "several large pharmaceutical clients."

Despite the findings of the Hopkins study, for practical and economic reasons many diagnostic laboratories currently only sequence tumor samples or do not believe the tumor-normal approach is necessary.

Last December, Good Start Genetics licensed the approach, called FAST-SeqS, for preimplantation genetic screening of embryos.

Rehm and LMM fellow Ozge Ceyhan-Birsoy will work with the Broad to develop a vision and strategic plan for its clinical lab.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.